Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 1035-1054

  Llaverias, Gemma ^a   Pou, Jordi ^a   Ros, Emilio ^b,c   Zambón, Daniel ^b,c   Cofán, Montserrat ^b,c   Sánchez, Alex ^a   Vázquez Carrera, Manuel ^a   Sánchez, Rosa M ^a   Laguna, Juan C ^a   Alegret, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Atovastatin; Familial combined hyperlipidemia; Gene expression; Monocytes

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ARACHIDONIC ACID; ATORVASTATIN; BLOOD CLOTTING FACTOR; CD36 ANTIGEN; CELL NUCLEUS ANTIGEN; COMPLEMENT; COMPLEMENTARY DNA; DEATH RECEPTOR 3; FATTY ACID; IMMUNOGLOBULIN; LIPID; LIPOPROTEIN LIPASE; PLACENTA PROTEIN 5; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CELL ISOLATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME METABOLISM; FAMILIAL HYPERLIPEMIA; GENE EXPRESSION PROFILING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LIPID ANALYSIS; MALE; MONOCYTE; NUCLEOTIDE SEQUENCE; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNINDEXED SEQUENCE;

AGED; GENE EXPRESSION PROFILING; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MONOCYTES; PYRROLES; TREATMENT OUTCOME;

EID: 50149107583     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.1035     Document Type: Article

References (40)

1. Hopkins PN, Heiss G, Ellison RC et al.: Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108, 519-523 (2003).
2. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD: Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 23, 1289-1294 (2003).
3. Meijssen S, Castro-Cabezas M, Twickler TB, Jansen H, Erkelens DW: In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J. Lipid Res. 41, 1096-1102 (2000).
4. de Graaf J, Veerkamp MJ, Stalenhoef AF: Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J. R. Soc. Med. 95(Suppl. 42), 46-53 (2002).
5. Lee JC, Lusis AJ, Pajukanta P: Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Curr. Opin. Lipidol. 17, 101-109 (2006).
6. van der Vleuten GM, Isaacs A, Hijmans A, van Duijn CM, Stalenhoef AF, de Graaf J: The involvement of upstream stimulatory factor 1 (USF1) in Dutch patients with familial combined hyperlipidemia. J. Lipid Res. 48(1), 193-200 (2006).
7. Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, Naoumova RP: Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J. Thromb. Haemost. 3, 677-685 (2005).
8. Batliwalla FM, Li W, Ritchlin CT et al.: Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. 11(1-12), 21-29 (2006).
9. Morello F, de Bruin TW, Rotter JI et al.: Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 2149-2154 (2004).
10. Osterud B, Bjorklid E: Role of monocytes in atherogenesis. Physiol. Rev. 83, 1069-1112 (2003).
11. Zambon D, Ros E, Rodriguez-Villar C et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 48, 47-54 (1999).
12. Gomez-Gerique JA, Gutierrez-Fuentes JA. Montoya MT et al.: [Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group]. Med. Clin. (Barc.) 113, 730-735 (1999).
13. Veerkamp MJ, de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF: Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 109, 2980-2985 (2004).
14. Junyent M, Gilabert R, Zambon D et al.: The use of Achilles tendon sonography to distinguish familial hypercholesterolernia from other genetic dyslipidemias. Arterioscler. Thromb. Vasc. Biol. 25, 2203-2208 (2005).
15. Pocovi M, Civeira F, Alonso R, Mata P: Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin. Vasc. Med. 4, 67-74 (2004).
16. Stein EA, Black DM: Lipoprotein changes with statins. Curr. Atheroscler. Rep. 4, 14-18 (2002).
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502 (1972).
18. Junyent M, Zambon D, Gilabert R, Cofan M, Nunez I, Ros E: Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio. Atherosclerosis 197, 740-746 (2008).
19. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159 (1991).
20. Kerr MK: Design considerations for efficient and effective microarray studies. Biometrics 59, 822-828 (2003).
21. Peng X, Wood CL, Blalock EM, Chen KC, Landfield PW, Stromberg AJ: Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics 4, 26 (2003).
22. Irizarry RA, Hobbs B, Collin F et al.: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
23. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article 3 (2004).
24. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57, 289-300 (1995).
25. Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA: Global functional profiling of gene expression. Genomics 81, 98-104 (2003).
26. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43 (2004).
27. Febbraio M, Hajjar DP, Silverstein RL: CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest 108, 785-791 (2001).
28. Ruiz-Velasco N, Dominguez A, Vega MA: Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol. 67, 303-313 (2004).
29. Clee SM, Bissada N, Miao F et al.: Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J. Lipid Res. 41, 521-531 (2000).
30. Reiner G, Oliver M, Skamene E, Radzioch D: Induction of tumor necrosis factor α gene expression by lipoprotein lipase requires protein kinase C activation. J. Lipid Res. 35, 1413-1421 (1994).
31. Beauchamp MC, Letendre E, Renier G: Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholestemlemia. J. Lipid Res. 43, 215-222 (2002).
32. Rubin C, Gur G, Yarden Y: Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res. 15, 66-71 (2005).
33. Lamb DJ, Modjtahedi H, Plant NJ, Ferns GA: EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques. Atherosclerosis 176, 21-26 (2004).
34. Borysenko CW, Furey WF, Blair HC: Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis. Biocbem. Biophys. Res. Commun. 328, 794-799 (2005).
35. Chinnaiyan AM, O'Rourke K, Yu GL et al.: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Biochem. Biophys. Res. Commun. 274, 990-992 (1996).
36. Bobik A, Kalinina. N: Tumor necrosis factor receptor and ligand superfamily family members TNFRSF14 and LIGHT: new players in human atherogenesis. Arterioscler. Thromb. Vasc. Biol. 21, 1873-1875 (2001).
37. Kang YJ, Kim WJ, Bae HU et al.: Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29, 229-235 (2005).
38. Crawley JT. Goulding DA, Ferreira V, Severs NJ, Lupu F: Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler. Thromb. Vasc. Biol. 22, 218-224 (2002).
39. Tuomisto TT, Korkeela A. Rutanen J et al.: Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase. colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler: Thromb. Vasc. Biol. 23, 2235-2240 (2003).
40. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).